¼¼°èÀÇ ¿¬±¸¿ë Ç×ü ¹× ½Ã¾à ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À² ºÐ¼®(Á¦Ç°º°, Á¾·ùº°, ¾÷Á¾º°, ¿ø·áº°, Çü»óº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°) - »ê¾÷ ¼ö¿ä ¿¹Ãø(-2030³â)
Research Antibodies and Reagents Market Size and Share Report by Product, Type, Vertical, Source, Form, Technology, Application, End User - Global Industry Demand Forecast to 2030
»óǰÄÚµå : 1463763
¸®¼­Ä¡»ç : Prescient & Strategic Intelligence Private Limited
¹ßÇàÀÏ : 2024³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 330 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,900 £Ü 6,844,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,400 £Ü 8,940,000
Printable PDF (Group User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,400 £Ü 11,733,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÁÖ¿ä ÇÏÀ̶óÀÌÆ®

¼¼°èÀÇ ¿¬±¸¿ë Ç×ü¡¤½Ã¾à ½ÃÀåÀº 2023³â¿¡ 120¾ï ´Þ·¯, 2030³â¿¡´Â 187¾ï ´Þ·¯ ±Ô¸ð¿¡ ´ÞÇϸç, 6.7%ÀÇ CAGR·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

ÀÓ»ó Áø´Ü¡¤Ä³¸®¾î ½ºÅ©¸®´×¡¤½Å¾à¿¡ ´ëÇÑ ¿ä±¸ÀÇ Áõ°¡¿Í À¯Àü¼º ÁúȯÀÇ ±ÞÁõÀÌ ¾÷°èÀÇ ¼ºÀåÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ÀλçÀÌÆ®

½Ã¾à Ä«Å×°í¸®´Â 2023³â¿¡ ¾à 60%·Î ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇϰí ÀÖÀ¸¸ç, ÀÌ 10³â°£Àº ÀÌ µ¿ÇâÀÌ °è¼ÓµÉ Àü¸ÁÀÔ´Ï´Ù.

1Â÷ Ç×ü´Â 2023³â¿¡ ¾à 70%ÀÇ Á¡À¯À²·Î ¾÷°è¸¦ ¼±µµÇϸç, ¾ÕÀ¸·Îµµ °è¼Ó ¼±µµÇÒ Àü¸ÁÀÔ´Ï´Ù.

¾Ï¿µ¿ªÀº 2023³â ½ÃÁ¡¿¡ ¾à 35%·Î ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇϸç ÁÖ¿ä Áö¿ª¿¡¼­ ¾ÏÀÌȯÀ²ÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀ¸·Î ÀÎÇØ ÀÌ 10³â°£ Ãִ븦 À¯ÁöÇÒ Àü¸ÁÀÔ´Ï´Ù.

ºÏ¹Ì´Â 2023³â¿¡ ¾à 55%ÀÇ Á¡À¯À²·Î ¾÷°è¸¦ ¼±µµÇϰí ÀÖÀ¸¸ç, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿Í ÀǾàǰÀÇ ¿¬±¸°³¹ß Ȱµ¿ÀÌ ¹ø¼ºÇÑ °ÍÀ¸·Î ÀÎÇØ ÇâÈÄ ¼ö³â°£ °ß°íÇÑ ¼ºÀåÀ» º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÌ 10³â°£ °¡Àå ºü¸¥ ¼Óµµ·Î ÃßÁøÇÒ Àü¸ÁÀÔ´Ï´Ù. À̰ÍÀº ÀÌ Áö¿ªÀÇ ±¹³»¿Ü ÀǷᡤ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷À¸·ÎºÎÅÍÀÇ ÀÚ±ÝÁ¶´ÞÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù.

¼¼°èÀÇ ¿¬±¸¿ë Ç×ü¡¤½Ã¾à ½ÃÀåÀ» ºÐ¼®ÇßÀ¸¸ç, ½ÃÀåÀÇ ±âº» ±¸Á¶¡¤ÃֽŠ»óȲ ¹× ÁÖ¿ä ÃËÁø¡¤¾ïÁ¦¿äÀÎ, ¼¼°è Àüü ¹× Áö¿ªº°¡¤ÁÖ¿ä ±¹°¡ÀÇ ½ÃÀå ±Ô¸ð µ¿Çâ Àü¸Á(±Ý¾× ±â¹Ý, 2017-2030³â), Á¦Ç°º°¡¤Á¾·ùº°¡¤¾÷Á¾º°¡¤¿ø·áº°¡¤Çü»óº°¡¤±â¼úº°¡¤¿ëµµº°¡¤ÃÖÁ¾»ç¿ëÀÚº° »ó¼¼ µ¿Çâ, ÇöÀçÀÇ ½ÃÀå °æÀï »óȲ, ÁÖ¿ä ±â¾÷ÀÇ °³¿ä µîÀ» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ÁöÇ¥

Á¦5Àå ¾÷°è Àü¸Á

Á¦6Àå ¼¼°è ½ÃÀå

Á¦7Àå ºÏ¹Ì ½ÃÀå

Á¦8Àå À¯·´ ½ÃÀå

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä« ½ÃÀå

Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦12Àå ¹Ì±¹ ½ÃÀå

Á¦13Àå ij³ª´Ù ½ÃÀå

Á¦14Àå µ¶ÀÏ ½ÃÀå

Á¦15Àå ÇÁ¶û½º ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦18Àå ½ºÆäÀÎ ½ÃÀå

Á¦19Àå ÀϺ» ½ÃÀå

Á¦20Àå Áß±¹ ½ÃÀå

Á¦21Àå Àεµ ½ÃÀå

Á¦22Àå È£ÁÖ ½ÃÀå

Á¦23Àå Çѱ¹ ½ÃÀå

Á¦24Àå ºê¶óÁú ½ÃÀå

Á¦25Àå ¸ß½ÃÄÚ ½ÃÀå

Á¦26Àå »ç¿ìµð¾Æ¶óºñ¾Æ ½ÃÀå

Á¦27Àå ³²¾ÆÇÁ¸®Ä«°øÈ­±¹ ½ÃÀå

Á¦28Àå ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE) ½ÃÀå

Á¦29Àå °æÀï ±¸µµ

Á¦30Àå ±â¾÷ °³¿ä

Á¦31Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Key Highlights

The research antibodies & reagents market generated USD 12.0 billion in 2023, and it will touch USD 18.7 billion, with a 6.7% CAGR, by 2030.

The rising need for clinical diagnostics, carrier screening, and new drugs, along with the surging incidence of genetic disorders is aiding the industry's growth.

The swift technological improvement in pharmaceutical platforms, the substantial application of antibodies & reagents in biotechnology & pharmaceutical analyses, and growing funding and initiatives from private and government bodies for large-scale biotechnology projects resulted in the industry expansion.

The rising research activities to produce new medicines, get them into trials and have them approved boost this industry.

Governments are funding in such activities because of the increasing incidence of chronic and infectious ailments, for discovering effective treatments.

Therefore, life sciences research activities have shattered some records in terms of scientific advancements, funding, and the variety and quantity of new medicines that are accessible to patients across the globe.

The market made some ground-breaking contributions during the pandemic of COVID-19 in the form of vaccines and therapeutics, assisted by the effective application of various research antibodies & reagents.

Key Insights

The reagents category accounted for the largest share of the industry in 2023, of approximately 60%, and it will continue this trend throughout this decade.

The growing application of biotechnology and biosciences in the pharmaceutical and healthcare sectors and the increasing biotechnical and pharmaceutical research for finding more effective, new drugs are driving the reagents category.

Primary antibodies led the industry in 2023, with approximately 70% share, and it will remain leading in the coming years.

The growth in the primary antibodies is because of the extensive variety of utilities offered by these antibodies in the R&D space; and the increasing availability of primary antibodies using goats, mice, rabbits, and various other species as hosts.

The oncology category was the largest contributor to the industry in 2023, with approximately 35% share, and it will remain the largest during this decade, because of the increasing incidence of cancer in key geographies.

The mice category led the industry because of the smaller size and high reproduction rate of the antibodies & reagents produced using mouse tissue.

The western blotting category is leading the market because of the extensive accessibility and acceptance of this method in healthcare R&D.

Monoclonal antibodies led the industry, due to the rising count of cancer research projects, which require antibodies with high specificity.

Proteomics was the largest contributor in 2023, with approximately 40% share, and it will further propel at a robust rate in the coming years.

The demand for greater effectiveness when mapping drug-protein and protein-protein interactions is boosting the proteomics category.

North America led the industry in 2023, with a share of approximately 55%, and it will advance at a robust rate in the coming years, owing to the substantial biotechnology and pharmaceutical R&D activities.

APAC will propel at the fastest rate during this decade, owing to the increasing funding from both foreign and domestic healthcare and biotechnology firms in this region.

The research antibodies & reagents industry is dynamic and competitive. Competition is powered by technological improvements, the specific demands of different research areas, and product innovation.

Table of Contents

Chapter 1. Research Scope

Chapter 2. Research Methodology

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

Chapter 6. Global Market

Chapter 7. North America Market

Chapter 8. Europe Market

Chapter 9. APAC Market

Chapter 10. LATAM Market

Chapter 11. MEA Market

Chapter 12. U.S. Market

Chapter 13. Canada Market

Chapter 14. Germany Market

Chapter 15. France Market

Chapter 16. U.K. Market

Chapter 17. Italy Market

Chapter 18. Spain Market

Chapter 19. Japan Market

Chapter 20. China Market

Chapter 21. India Market

Chapter 22. Australia Market

Chapter 23. South Korea Market

Chapter 24. Brazil Market

Chapter 25. Mexico Market

Chapter 26. Saudi Arabia Market

Chapter 27. South Africa Market

Chapter 28. U.A.E. Market

Chapter 29. Competitive Landscape

Chapter 30. Company Profiles

Chapter 31. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â